Merck Sharp & Dohme Corp. v. Angels Pharma India Private Limited

In the high-stakes world of pharmaceuticals, a single molecule can be worth billions—and the race to copy it can begin the moment a patent is granted. When a global pharma giant discovered a domestic player gearing up to manufacture its patented diabetes drug, it didn't wait for a full trial to act. The result was a decisive interim victory that underscored just how seriously courts take the protection of essential public health drugs.

Merck Sharp & Dohme Corp., a globally recognized pharmaceutical innovator, held Indian Patent No. 209816, which covered Sitagliptin—a critical drug used in the treatment of type 2 diabetes. Merck, along with a co-plaintiff, had invested heavily in researching, developing, and bringing this molecule to market. The defendants, Angels Pharma India Private Limited, were allegedly preparing to manufacture and launch a version of the same drug, which Merck claimed would directly infringe upon its patent rights. Faced with the prospect of an imminent launch by a competitor, Merck moved the court seeking urgent interim relief to stop the alleged infringement in its tracks.

Merck Sharp & Dohme argued that Angels Pharma's intended manufacture and sale of Sitagliptin would constitute a clear infringement of their valid and subsisting patent. They emphasized the public health significance of the drug and the irreparable harm that would be caused if a generic version entered the market while the patent was still in force. On the other side, Angels Pharma India Private Limited contested the claims, pushing back against the allegations of infringement. The legal friction centered on whether Merck had done enough at this preliminary stage to convince the court that its patent was being violated, and whether the harm to Merck outweighed any inconvenience caused to the defendant by halting their manufacturing plans.

The court ruled in favor of Merck Sharp & Dohme Corp., finding that the plaintiffs had successfully established a prima facie case of patent infringement. The court was satisfied that the balance of convenience lay firmly in Merck's favor, particularly given that Sitagliptin was an essential public health drug. Based on these findings, the court granted interim relief to the plaintiffs, effectively restraining Angels Pharma India Private Limited from manufacturing or commercializing the infringing product until the matter could be fully adjudicated.

For founders and IP professionals in the pharmaceutical space, this case is a powerful reminder that interim injunctions are not just theoretical remedies—they are real, accessible tools when the legal criteria are met. If you hold a valid patent on an essential drug, act swiftly the moment you detect an impending infringement. Building a strong prima facie case and demonstrating that the balance of convenience favors you can secure immediate relief, protecting both your investment and public trust in your innovation.